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Abstract: 68Ga-PSMA-11 positron-emission tomography/computed tomography (PET/CT) is
commonly used for restaging recurrent prostate cancer (PC) in European clinical practice. The goal of
this study is to determine the optimum time for performing these PET/CT scans in a large cohort of
patients by identifying the prostate-specific-antigen (PSA) and PSA kinetics thresholds for detecting
and localizing recurrent PC. This retrospective analysis includes 581 patients with biochemical
recurrence (BC) by definition. The performance of 68Ga-PSMA-11 PET/CT in relation to the PSA value
at the scan time as well as PSA kinetics was assessed by the receiver-operating-characteristic-curve
(ROC) generated by plotting sensitivity versus 1-specificity. Malignant prostatic lesions were identified
in 77%. For patients that were treated with radical prostatectomy (RP) a PSA value of 1.24 ng/mL
was found to be the optimal cutoff level for predicting positive and negative scans, while for
patients previously treated with radiotherapy (RT) it was 5.75 ng/mL. In RP-patients with PSA value
<1.24 ng/mL, 52% scans were positive, whereas patients with PSA ≥1.24 ng/mL had positive scan
results in 87%. RT-patients with PSA <5.75 ng/mL had positive scans in 86% and for those with PSA
≥5.75 ng/mL 94% had positive scans. This study identifies the PSA and PSA kinetics threshold levels
for the presence of 68Ga-PSMA-11 PET/CT-detectable PC-lesions in BC patients.
Keywords: 68Gallium-PSMA PET/CT; prostate-specific-antigen; prostate cancer; PSA kinetics
thresholds; biochemical recurrence; optimal cutoff level
1. Introduction
Prostate cancer (PC) is the second most common type of malignant cancers and it accounts for 55%
of global cancer incidence, together with lung, stomach, and breast cancer [1]. The global incidence of
PC in 2012 is 1.1 million per year and accounts for approximately 7% of deaths in men [2]. PC incidence
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has increased to 95–116 per 10,000 persons and the incidence of death related to PC is 2 per 10,000 per
person years since the introduction of prostate-specific-antigen (PSA)-screening [3].
Most patients with BC of PC are diagnosed at an early tumor stage with local disease. The primary
treatment of choice for localized PC is radical prostatectomy (RP) or radiation therapy (RT). In recent
years, several alternative treatment options have been approved, especially for the therapy of aggressive
PC and/or metastatic spread [4,5]. BC occurs in about 30% of the patients treated, in spite of radical
therapy [5,6]. BC is defined as a PSA is > 0.2 ng/mL after radical prostatectomy (RP) or > 2 ng/mL
above the nadir following radiotherapy (RT) [7]. The shorter the time between primary treatment and
BC is, the greater the risk for metastatic recurrence and clinical progression will be. In comparison, the
longer the timeline, the higher the association of localized recurrence [4]. In this setting, PSA and PSA
kinetics (i.e., PSA doubling time (PSAdt)—“which measures the exponential increase in serum PSA
over time” [8] and PSA velocity (PSAvel)—an indication of the “absolute annual increase in serum PSA
(ng/mL/year)” [8]) are valuable for the forecast of recurrent PC [4,9]. However the PSA alone does not
indicate the localization of malignant lesions.
Cornford et al. shows imaging guidelines and salvage therapy protocols after primary treatment [7].
In patients with presumptive cancer after initial curative treatment, diagnostic imaging is challenging
in the evaluation of patients with recurrent PC and/or distant metastases. Current standard imaging
techniques for restaging include transrectal ultrasonography (TRUS), 99mTc-diphosphonate bone
scintigraphy, computed tomography (CT), and magnetic resonance imaging (MRI). Morphological
imaging modalities, such as CT and MRI, often fail to visualize cancer lesions. Therefore, their accuracy
is limited, especially for the detection of lymph node metastases (LNM). Other diagnostic methods,
such as positron-emission tomography (PET) (with various tracers) or MR spectroscopy, which show
metabolic activity, will be used, in order to minimize this limitation [10].
Hybrid PET/CT has been favored for several years and has been applied according to
international guidelines to improve the diagnostic accuracy [8,11]. 68Gallium (Ga)-prostate specific
membrane antigen (PSMA) is currently one of the most successful tracers for PC imaging due
to its clinical specificity [12,13]. PSMA is a transmembrane protein that is overexpressed in 95%
of PC cells, especially in higher grade PC, recurrent PC and metastatic disease [14]. In benign
prostate tissue, it is only weakly or not expressed. PSMA provides an optimal target for the
diagnosis of PC as well as the treatment of PC [15]. Different 68Ga-labelled PSMA inhibitors
have been studied regarding their sensitivity and specificity to diagnose recurrence of PC
such as HBED-CC, which is an efficient 68Ga-chelator [13,16]. A German group has developed
Glu-NH-CO-NH-Lys(Ahx)-{68Ga-(N,N′-bis-[2-hydroxy-5-(carboxyethyl)benzyl]ethylen-ediamine-N,N′
-diacetic acid)}(68Ga-HBED-CC-PSMA or 68Ga-PSMA-11), a small-molecule inhibitor for PSMA [6,16].
The HBED-CC ligand has a fast blood and organ clearance and little of the ligand is taken up into the
liver. 68Ga-PSMA-11 PET/CT is a favorable diagnostic tool due to its excellent contrast-to-noise ratio
and the improved detection of lesions. The HBED-CC conjugated PSMA inhibitor 68Ga-PSMA-11
precisely binds to PSMA-positive cells and it is more specifically internalized into PSMA expressing
tumor cells and PSMA-positive metastatic lesion cells of PC [13,16,17]. In recent years, several other
PSMA ligands have been developed for labelling with 68Ga and 18F. In particular, the 18F-labelled
PSMA ligands continue to be researched [6,18,19]. To date, thousands of patients have been scanned
with 68Ga-PSMA, while 18F-PSMA has only been used in a few hundred patients.
The current research is directed toward the development of more sensitive PET molecules for
detection of BC at low PSA levels to allow for a personalized treatment planning at an early stage
of recurrent disease. PSA kinetics has been proposed to supplement other diagnostic modalities in
patient selection, especially with low PSA [9].
The goal of this study is to determine the best time for performing 68Ga-PSMA-11 PET/CT scans
in patients with BC by calculating PSA and PSA kinetics thresholds for the detection and localization
of recurrent PC.
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2. Results
2.1. Clinical Characteristics
Table 1 summarizes the clinical and pathological characteristics of the 581 study patients. At the
time of the scan, the median PSA levels were 2.98 ng/mL, range (0.2–2000). Gleason Score (GS,
the grading system for determining the aggressiveness of PC) [8] was for GS ≤ 6 in 37 patients.
303 patients had GS 7 (7a + 7b), 104 patients had GS 8, and 139 patients GS > 8. 36% of the patients were
treated with systemic androgen deprivation therapy (ADT). The primary treatment of most patients
(493) was radical prostatectomy (85%). 88 patients (15%) were primarily treated with radiotherapy
(Table 1).
Table 1. Patient characteristics.
Characteristics (n) Parameters




Mean ± SD 71.3 ± 7.5
Gleason Score (581)
≤ 6 (low risk + grade group 1) 37
7 (intermediate risk + grade group 2+3) 303
8 (high risk + grade group 4) 104












Mean ± SD 22.1 ± 48.8
Prior treatment of primary tumor (581)
Surgery (radical prostatectomy) 493




Total/PET/CT positive patients 450/581
Abbreviations: PSA, prostate-specific-antigen; vel, velocity; dt, doubling time; SD, standard deviation; n, number of
patients; y, year.
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2.2. Overall Positivity Rate of 68Ga-PSMA-11 PET/CT
68Ga-PSMA-11 PET/CT showed a positivity rate in 450 out of 581 patients (77%) (mean PSA 18.21
± 101.91 ng/mL). The discrimination of the PSA values between patients with a PSMA-positive scan
and those with a PSMA-negative scan was statistically significant (p < 0.001). The mean PSA levels of
patients with positive scans were significantly higher than those of patients with negative scan results
(22.94 ± 115.38 ng/mL versus 1.95 ± 3.28 ng/mL, p < 0.001, Mann-Whitney-U test) (Table 2).
Table 2. 68Ga-PSMA-11 positron-emission tomography/computed tomography (PET/CT)-11 positive
and negative scan results in relation to prostate-specific-antigen (PSA).
PET/CT Results PSA (ng/mL)
Mean ± SD Median (range) p Value
Positive (450/581) 22.94 ± 115.38 4.01 (0.2-2000)
Negative (131/581) 1.95 ± 3.28 0.8 (0.2–25.67)
Total 18.21 ± 101.91 2.98 (0.2–2000) p < 0.001 *
* Mann-Whitney-U test. Abbreviations: PSA, prostate-specific-antigen; SD, standard deviation; p < 0.05 is
considered significant.
This retrospective analysis includes 581 patients with a BC. We looked at the two groups of
patients with different BC by definition (patient-group RP and patient-group RT) separately to ensure
proper statistics and a homogeneous patient collective.
2.3. Positivity Rate of 68Ga-PSMA-11 PET/CT in Detecting Clinical Recurrence Post-Prostatectomy
68Ga-PSMA-11 PET/CT revealed malignant prostatic lesions in 370 of 493 patients (75%).
A statistically significant demarcation in PSA values was shown (p < 0.001) between patients with
a positive (3.20 ng/mL) and a negative (0.70 ng/mL) 68Ga-PSMA-11 PET/CT scan.
The detection efficacy of 68Ga-PSMA-11 PET/CT for post-prostatectomy (patient-group RP) was
40% (27) for PSA levels of 0.2 to < 0.5 ng/mL and 62% (48), 70% (61), 84% (99), 94% (135) for PSA levels
of 0.5 to < 1 ng/mL, 1 to < 2 ng/mL, 2 to < 5 ng/mL, and ≥ 5 ng/mL, respectively (p < 0.001) (Table 3A).
Table 3A shows the sites of lesions that were detected by 68Ga-PSMA-11 PET/CT scans in
patient-group RP. Local recurrence was evident in 29% (109/370) of the patients with a positive scan.
Out of all patients with positive scans, 85% showed metastases. 54% of these patients exhibited local
metastases and 23% distant metastases. Multiple metastases were observed in 66% of these patients.
Lymph node (LN) metastases (LNM) were evident in 78% of the patients, 75% of which were local,
8% distant LNM, and 18% were local and distant LNM. Bone metastases were revealed in 43% of
the patients with positive 68Ga-PSMA-11 PET/CT scans. Visceral metastases rarely occurred in 7%
(Table 3A). Single metastases were detected in 28% of the patients (n = 105) with positive 68Ga-PSMA-11
PET/CT results and 56% of the patients (n = 208) showed multiple PC metastases (Table 4).
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Table 3. (A) Prostate cancer (PC) recurrence (patient-group radical prostatectomy (RP)) location related
to different PSA values. (B) PC recurrence (patient-group RT) location related to different PSA values.
(A) Prostate cancer (PC) recurrence (patient-group radical prostatectomy (RP)) location related to different PSA
values.
PSA (ng/mL) 0.2–<0.5 0.5–<1.0 1.0–<2.0 2.0–<5.0 ≥5.0 Chi2, p
Number (x/493)
patient-group RP 67 78 87 118 143
PET/CT positive 27 48 61 99 135 r = 0.413; p < 0.001
Positivity rate 40.3% 61.5% 70.1% 83.9% 94.4%
Androgen deprivation
therapy 15 13 21 31 77 r = 0.252; p < 0.001
Regions:
Local recurrence 6 14 19 29 41 r = 0.149; p = 0.02
Metastases 22 39 49 80 123 r = 0.365; p < 0.001
Site of metastases: r = 0.402; p < 0.001
Local metastases 16 28 32 43 50
Distant metastases 3 7 12 18 31
Local + distant
metastases 3 4 5 19 42
Number of metastases: r = 0.397; p < 0.001
Single metastases 14 14 23 25 29
Multiple metastases 8 25 26 55 94
Lymph node metastases
(LNM) 19 30 38 61 97 r = 0.266; p < 0.001
Site of LNM: r = 0.344; p < 0.001
Local LNM 18 28 34 51 52
Distant LNM 0 0 2 4 13
Local + distant LNM 1 2 2 6 32
Bone metastases 8 11 12 33 72 r = 0.315; p < 0.001
Visceral metastases 1 1 2 5 12 r = 0.128; p = 0.075*
(B) PC recurrence (patient-group RT) location related to different PSA values.
PSA (ng/mL) 2.0–<5.0 ≥5.0 Chi2, p
Number (x/88)
patient-group RT 33 55
PET/CT positive 29 51 r = 0.08; p = 0.44
Positivity rate 87.9% 92.7%
Androgen deprivation
therapy 11 41 r = 0.406; p = 0.001
Regions:
Local recurrence 21 29 r = −0.107; p = 0.317
Metastases 14 37 r = 0.244; p = 0.022
Site of metastases: r = 0.306; p = 0.011
Local metastases 10 12
Distant metastases 1 13
Local + distant
metastases 3 12
Number of metastases: r = 0.289; p = 0.022
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Table 3. Cont.
Single metastases 6 7
Multiple metastases 8 30
Lymph node metastases
(LNM) 12 23 r = 0.054; n.s.
Site of LNM: r = 0.076; n.s.
Local LNM 9 17
Distant LNM 2 1
Local + distant LNM 1 5
Bone metastases 5 22 r = −0.261; p = 0.014
Visceral metastases 2 1 r = −0.113; n.s.
* Fisher exact test. Abbreviations: PSA, prostate-specific-antigen; LNM, lymph node metastases; p < 0.05 is
considered significant; r, Pearson correlation coefficient.
Table 4. Tumor location and positivity rate of detected lesions.
Tumor Location n (493) % (370) n (88) % (80)
PET/CT positive patients 370 80
Local recurrence 109 29.5% 50 62.5%
Metastases 313 84.6% 51 63.8%
local 169 45.7% 22 27.5%
distant 71 19.2% 14 17.5%
local and distant 73 19.7% 15 18.8%
single 105 28.4% 13 16.3%
multiple 208 56.2% 38 47.5%
Lymph node metastases 245 66.2% 35 43.8%
Local/regional 183 49.6% 26 32.5%
Distant 19 5.1% 3 3.8%
Local and distant 43 11.6% 6 7.5%
Bone metastases 136 36.8% 27 33.8%
Visceral metastases
(lung, liver, adrenals, soft
tissue, spleen, thyroid)
21 5.7% 3 7.5%
Abbreviation: n, number of patients.
2.4. Positivity Rate of 68Ga-PSMA-11 PET/CT in Detecting Clinical Recurrence Post-Radiotherapy
Overall, 80 of 88 patients had a positive 68Ga-PSMA-11 PET/CT scan (91%). The discrimination in
PSA values between the patients with a positive (7.15 ng/mL) and a negative (5.25 ng/mL) scan was
not statistically significant (p = 0.384).
For patients that were treated with RT, the detection efficacy of 68Ga-PSMA-11 PET/CT was 88%
(29) for PSA levels of 2 to < 5 ng/mL and 93% (51) for PSA levels of ≥ 5 ng/mL, respectively (p = 0.44)
(Table 3B).
Table 3B shows the sites of lesions that were detected by 68Ga-PSMA-11 PET/CT scans in
patient-group RT. In 63% (50/80) of the patients with a positive scan, local recurrence was detected.
Of the positive scans, 64% showed metastases and 43% of these patients exhibited local metastases,
whereas 27% showed at least one distant finding (extra pelvic LN and/or bone and/or visceral
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metastases). Multiple metastases were demonstrated in 75% of these patients. A total of 69% of the
patients showed LNM (74% of them local, 9% distant, and 17% local and distant LNM). Bone metastases
were revealed in 34% of the patients with positive 68Ga-PSMA-11 PET/CT scans. Visceral metastases
were detected in only 4% of the positive scans (Table 3B). Multimetastatic disease was shown in 48% of
the PSMA-positive patients (n = 38), whereas in 16% of the patients (n = 13) single PC metastases were
detected (Table 4).
2.5. PSA and PSA Kinetics Threshold Levels
The performance of 68Ga-PSMA-11 PET/CT in relation to the PSA value at the time of the scans,
as well as PSA kinetics, were assessed by receiver-operating-characteristic-curve (ROC) generated
by plotting sensitivity versus 1-specificity. A PSA value of 1.24 ng/mL was found to be the optimal
cutoff level for predicting positive and negative scans by means of ROC analysis (AUC = 0.788; 95% CI
0.746–0.831) in all the patients primarily treated with RP and with RT (the cohort of 581 patients).
2.6. PSA and PSA Kinetics Threshold Levels Post-Prostatectomy
The optimal cutoff level was also 1.24 ng/mL for patients that were treated with radical
prostatectomy (370/493 patient-group RP) (AUC = 0.784; 95% CI 0.740–0.828) (Figure 1).
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and bone metastases (18% vs. 82%, p < 0.001, r 0.235).  
Figure 1. Receiver-operating-characteristic-curve (ROC) curve for PSA (patient-group RP) with
an optimal cutoff level of 1.24 ng/mL.
In patients with a PSA value <1.24 ng/mL, 52% (92/177) 68Ga-PSMA-11 PET/CT scans were
positive, whereas patients with a PSA ≥1.24 ng/mL exhibited positive scan results in 87% (278/316)
(p < 0.001). Local recurrence in the prostate bed was noted in 13% vs. 27% of the patients with PSA
levels below and above the cutoff. Multimetastatic disease was determined in 21% of the patients with
PSA values that were below cutoff level vs. 79% of patients with PSA above cutoff (p < 0.001, r 0.315)
(Table 5A). The local and distant metastases were determined in 6% (11/177) of patients with PSA
values below the cutoff level vs. 20% (62/316) of patients with PSA above cutoff (p < 0.001) (Table 5A).
Local metastases were detected in 51 patients (29%) below and in 118 patients (37%) above cutoff PSA
values (p < 0.001). Distant lesions were identified in 9% below vs. 18% above cutoff levels, respectively
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(p < 0.001; Table 5A). As compared to patients with PSA values that were below the optimal cutoff
level, patients with PSA levels ≥ 1.24 more frequently exhibited LNM (25% vs. 75%, p < 0.001, r 0.228)
and bone metastases (18% vs. 82%, p < 0.001, r 0.235).
Table 5. (A) 68Ga-PSMA-11 PET/CT positivity rate (RP) of different subgroups related to PSA levels.
(B) 68Ga-PSMA-11 PET/CT positivity rate (RT) of different subgroups that were related to PSA levels.
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0.2 to <1
(145) 75 (51.7%) 28 (19.3%) 33 (22.8%)
<1.24 (177) 92 (52%) 33 (31%) 44 (21%)
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(145) 20 (13.8%) 44 (30.3%) 10 (6.9%) 7 (4.8%)
<1.24 (177) 23 (13%) 51 (28.8%) 15 (8.5%) 11 (6.2%)
≥1.24 (316) 86 (27.2%) 118 (37.3%) 56 (17.7%) 62 (19.6%)
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Metastases Multiple Metastases p/r Value
<5.75 (36) 31 (86.1%) 15 (41.7%) 19 (52.8%)
≥5.75 (52) 49 (94.2%) 7 (13.5%) 29 (55.8%)
Total (88) 80 (91%) p = 0.19; r0.139 22 48














<5.75 (36) 22 (61.1%) 11 (30.6%) 1 (2.8%) 4 (11.1%)
≥5.75 (52) 28 (53.8%) 11 (21.2%) 13 (25%) 11 (21.2%)
Total (88) 50 p = 0.5; r
−0.07 22 14 15
p = 0.01; r
0.286
Abbreviations: PSA, prostate-specific-antigen; p < 0.05 is considered significant; r, Pearson correlation coefficient.
The optimal PSAvel threshold from ROC analysis for the detection of recurrent PC-lesions
(patient-group RP) was 1.32 ng/mL/year (AUC = 0.777; 95% CI 0.709–0.845) (Figure 2), which showed
significant differences between the PET-positive and PET-negative scans (p < 0.001).
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2.7. PSA and PSA Kinetics Threshold Levels Post-Radiotherapy
The optimal cutoff level for patients that were previously been treated with RT (80/88 patient-group
RT) was 5.75 ng/mL (AUC = 0.594; 95% CI 0.400–0.788) (Figure 3). In patients with a PSA value
<5.75 ng/mL, 86% (31/36) 68Ga-PSMA-11 PET/CT scans were positive, whereas patients with a PSA
≥5.75 ng/mL exhibited positive scan results in 94% (49/52) (p = 0.19, r 0.139). Local recurrence in the
prostate appeared in 61% vs. 54% of the patients with PSA levels that were below and above cutoff,
respectively. Multimetastatic disease was determined in 53% of the patients with PSA values that were
below cutoff level vs. 56% of patients with PSA above cutoff (p = 0.008, r 0.255) (Table 5B). Local and
distant metastases were found in 11% (4/36) of patients with PSA values below cutoff level vs. 21%
(11/52) of patients with PSA above cutoff (p = 0.01, r 0.286) (Table 5B). Patients with PSA levels ≥ 5.75
more frequently exhibited LNM (33% vs. 41%, p = 0.393, r 0.076) and bone metastases (26% vs. 41%,
p = 0.089, r 0.152) as compared to patients with PSA values below the optimal cutoff level.
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An optimal PSAvel threshold from ROC analysis for the detection of recurrent PC-lesions
(patient-group RT) could not be ascertained, since only 19 patient data sets were available for the
calculation of the value, of which a positive scan result was obtained in 18 patients.
ROC curve analysis revealed a PSAdt threshold of 10.6 months (AUC = 0.600; 95% Cl 0.366–0.834)
to distinguish patients with positive and negative 68Ga-PSMA-11 PET/CT, but without significance
(p = 0.353).
2.8. Maximum Standardized Uptake Value (SUVmax)
As evidenced by the Kolmogorov-Smirnov-Test, the SUVmax of the detected sites of malignant
lesions were not normally distributed. SUVmax was the highest in bone metastases (mean and standard
deviation/SD: 22.14 ± 22.98, median: 15) and lowest in lung metastases (mean and SD: 9.84 ± 9.31,
median: 6). SUVmax of LNM and visceral metastases showed values in between.
2.9. GS
4% of patients with a positive 68Ga-PSMA-11 PET/CT scan were categorized as being low risk PC
(International Society of Urological Pathology (ISUP) grade 1; GS < 7), whereas 12% of PSMA-positive
patients were categorized GS 7a (ISUP grade 2; intermediate risk), 35% GS 7b (ISUP grade 3; intermediate
risk), 22% GS 8 (ISUP grade 4; high risk), and 26% GS > 8 (ISUP grade 5; high risk) [8] (Table 6).
High risk (GS 8, GS > 8) as compared to low risk patients (GS < 7) showed a high frequency of positive
scan results (p < 0.001) and metastases (52% vs. 2%) (p < 0.001). When considering local recurrence,
the results are similar, but not statistically significant. With regard to the subgroups (GS 7a vs. GS 7b),
there is an important distinction between patients with intermediate risk and grade group 2 (GS 7a
also called 7 (3 + 4)) (10%) when compared to patients with intermediate risk and grade group 3 (GS
7b also called 7 (4 + 3)) (36%) for PSMA-positive metastases (p < 0.001) (Table 6).
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Table 6. Gleason Score in relation to 68Ga-PSMA-11 PET/CT-11 positive scan results.
n = 581 GS < 7 (37) GS 7a (97) GS 7b(204) GS 8(104)
GS >
8(139) Chi
2 r, p Value
PET/CT positive
(450/581) 16 52 158 97 117 0.288; p < 0.001
Local recurrence
(159/581) 9 24 56 32 38 0.027; n.s.
Metastases
(364/581) 8 36 132 83 105 0.324; p < 0.001
Abbreviations: GS, Gleason Score; n, number of patients; p < 0.05 is considered significant; r,
Pearson correlation coefficient.
2.10. ADT
ADT was significantly associated with increased probability of a positive 68Ga-PSMA-11 PET/CT
scan (p < 0.001). 37% of PSMA PET/CT-positive and 18% of PSMA PET/CT-negative patients were
treated with ADT (p < 0.001, r 0.173) in the patient-group RP. For the patient-group RT, 59% of the
patients with a positive PSMA scan and 63% with a negative scan were treated with androgens
(p = 0.837, r =™0.022).
2.11. Alkaline Phosphatase (AP)
AP has been described as an efficient and functional biomarker for the prognosis of PC (43).
We wanted to verify whether AP is a predictor for bone involvement of PC. In our study, AP levels
of patients with positive 68Ga-PSMA-11 PET/CT scan results were higher than those of patients with
negative scans (93 ± 53 IU/L vs. 74 ± 24 IU/L, p < 0.001, Mann-Whitney-U test). Patients exhibiting
bone metastases showed higher AP than patients without bone metastases (108 ± 70 IU/L vs. 76 ± 23
IU/L; p < 0.001).
2.12. Subpopulation
EAU guidelines suggest PSMA PET/CT for restaging PC in the case of patients that were treated
with RP, if the PSA level is > 0.2 ng/mL and if the results would influence subsequent treatment
decisions [8]. In the event that PSMA PET/CT is not available and the PSA level is ≥ 1 ng/mL, PET/CT
with other tracers (Fluciclovine or Choline) has been suggested, if the results could influence subsequent
treatment decisions [8]. For PSA recurrence after RT, EAU guidelines recommend performing PSMA
PET/CT (if available) or fluciclovine PET/CT or choline PET/CT in patients that qualified for curative
salvage treatment [8]. Therefore, we analyzed the PSA range from 0.2 ng/mL to < 1 ng/mL for
post-prostatectomy patients. We did not form a separate subgroup for the irradiated patients, as no
PSA threshold was stated in the EAU guidelines with regard to them.
All of the prostatectomized patients, 29% (145/493) exhibited PSA levels between 0.2 and < 1 ng/mL
and 52% of these patients showed positive PET/CT scans (positive: 0.2 to < 0.5 ng/mL 40% and 0.5 to
< 1 ng/mL 62%; p < 0.001, r 0.413) (Table 3A). In this subpopulation (overall positivity rate in scans
and PSA levels between 0.2 ng/mL and < 1 ng/mL), 68Ga-PSMA-11 PET/CT showed the presence of
local recurrence in the prostate bed in 27% (20 of 75), of local metastases in 59% (44 of 75), of distant
metastases in 13% (10 of 75), and of local and distant metastases in 9% (7 of 75). Multimetastatic
carcinoma was detected in 44% (33 of 75) (Table 3A). The absolute PSA value at the time of the
68Ga-PSMA-11 scan was associated with an increased probability of a positive scan result (p < 0.001).
3. Discussion
We evaluated 68Ga-PSMA-11 PET/CT scans in 581 BC patients after primary curative PC therapy
(RP as well as RT) in this retrospective study. A high positivity rate of 77% (450/581 patients) for the
detection of malignant prostatic lesions was shown (Figure 4A,B)). Our data reflects the positive results
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of several other studies and confirms that 68Ga-PSMA-11 PET/CT is a promising method for diagnosing
PC [12,20–24]. For restaging prostatectomized BC patients by PSMA PET/CT, the EAU guidelines
recommend a PSA level of > 0.2 ng/mL [8]. Patients with low cancer burdens have the best chance of
a salvage RT to be curative. For this reason, imaging with subsequent therapy planning at an early
stage of recurrent disease makes sense, from the point at which carcinoma foci are detectable, even with
low PSA [25]. The EAU guidelines report that salvage RT in BC patients after RP was correlated with
a tripling in PC-specific survival when compared to the patients who did not get salvage therapy [8].
The purpose of our study was to determine the best time for performing 68Ga-PSMA-11 PET/CT scans
in BC patients. For that reason, we calculated the PSA and PSA kinetics thresholds for the detection
and localization of recurrent PC. The PSA levels and PSA kinetics were assessed by ROC generated by





Figure 4. (A) History of a patient with prostate cancer followed by radical prostatectomy and 
lymphadenectomy (pT3, pN0, cM0, G3) in 2012. PSA doubles within three months. 68Ga-PSMA-11 
PET/CT scan shows two lymph node metastases with high prostate specific membrane antigen 
(PSMA)-avidity. (B) The two small lymph node metastases are detectable on CT alone, but not suspect 
of malignancy. 
3.1. Overall Positivity Rate 
The positivity rate of 68Ga-PSMA-11 PET/CT of the present study was 77% over all patients 
(mean PSA 22.94 ± 115.38 ng/mL), thereby confirming the results of previous studies where detection 
rates of 74% to 83% were reported for restaging PET/CT [6,12,26]. There was a statistically significant 
ability to discriminate PSA values between PSMA-positive and PSMA-negative scans (p < 0.001). The 
overall patient group was divided into the group of patients who were primarily treated with 
Figure 4. (A) History of a patient with prostate cancer followed by radical prostatectomy and
lymphadenectomy (pT3, pN0, cM0, G3) in 2012. PSA doubles within three months. 68Ga-PSMA-11
PET/CT scan shows two lymph node metastases with high prostate specific membrane antigen
(PSMA)-avidity. (B) The two small lymph node metastases are detectable on CT alone, but not suspect
of malignancy.
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3.1. Overall Positivity Rate
The positivity rate of 68Ga-PSMA-11 PET/CT of the present study was 77% over all patients (mean
PSA 22.94 ± 115.38 ng/mL), thereby confirming the results of previous studies where detection rates of
74% to 83% were reported for restaging PET/CT [6,12,26]. There was a statistically significant ability to
discriminate PSA values between PSMA-positive and PSMA-negative scans (p < 0.001). The overall
patient group was divided into the group of patients who were primarily treated with prostatectomy
(patient-group RP) and the group of patients who were primarily treated with RT (patient-group RT)
to ensure clean statistics.
3.2. Positivity Rate (RP)
In the group of prostatectomized patients, the positivity rate was 75% (370/493 patients) (see
Table 3A). Therefore, a clinically relevant percentage of patients with low PSA levels (< 0.5 ng/mL) could
be diagnosed with the recurrence of PC, being comparable to the results of other studies [6,12,23,26].
In recent studies of restaging by 68Ga-PSMA PET/CT, the detection rate was 50% at PSA levels of 0.2 to
0.49 ng/mL [6] and, in another study, 57.9% of the patients were 68Ga-PSMA PET/CT-positive at PSA
levels from 0.2 to < 0.5 ng/mL [20]. The results from the present study emphasize that 68Ga-PSMA
PET/CT is a sensitive tool for restaging PC, even at low PSA values [23]. After early salvage RT (PSA ≤
0.5 ng/mL), an undetectable PSA level can be reached in 60% of the patients, being associated with
a chance of 80% for a progression free five-year survival. This is indicated as second line therapy
with curative intent [8,25]. Salvage RT is usually indicated after a persistent increase in PSA after RP,
when systemic metastases are not found during staging imaging. If conventional imaging does not
show any malignant foci (local and/or distant metastases), only the prostate bed is typically irradiated
by Radiation Oncologists. Eiber et al. described that the detection of malignant lesions by PET was
extremely important for the final diagnosis in over 50%. They showed lesions that were not detected
by computed tomography (CT) [20,23]. Another study demonstrated that, in patients with BC after RP
while using the standard procedure, nearly 20% of 68Ga-PSMA PET/CT-positive lesions—suspicious of
malignancy—would not have been included in the radiation field. All of these patients belonged to
the crucial collective with PSA of < 1 ng/mL. 68Ga-PSMA-11 PET/CT hybrid imaging opens up the
possibility of changing the therapy [23,27]. Based on the data, both radiation therapists and urologists
should have a more accurate road map for directing therapy. In the end, the radiation therapist should
point where to direct his device. If a LN is resectable, a urologist might also resect it.
In comparison to other radiopharmaceuticals (e. g. 11C- and 18F-choline), detection rates of
68Ga-PSMA at low PSA levels were higher [28,29]. PSA levels and 11C-choline scans with positive
results were linearily correlated [30–32]. The positivity rate of 11C-choline scans for restaging was 73%
at PSA levels of ≥ 3 ng/mL, but at PSA < 1 ng/mL the rate decreased dramatically to 19–36% [4,28].
However, a recent study showed that the second-generation of labelling of PSMA tracers with 18F
(e.g., 18F-DCFPyL-PSMA) was superior to 68Ga-PSMA for restaging at PSA levels of 0.5 to 3.5 µg/L
with a sensitivity of 88% (15 of 17 patients) vs. 66% (23 of 35 patients). But at PSA values < 0.5 and >
3.5 µg/L, the sensitivity of both methods was comparable. Nevertheless, in 36% of the patients with
positive scans, additional lesions were found, while using 18F-PSMA vs. 68Ga-PSMA [18]. Overall, the
results of both methods were demonstrated to be similar [18]; this was also shown in a recent study,
which compared 68Ga-PSMA-11 and 18F-PSMA-1007 in the case of staging PC [33].
3.3. Positivity Rate (RT)
The positivity rate of RT patients was 91%, but no statistically significant differences could be
shown in the distinction of PSA levels between patients with positive and negative scans (p = 0.384)
(see Table 3B). The EAU Guidelines recommend that PSMA PET/CT can be crucial for PC detection in
the setting of BC after RT. However, they suggest that further studies be conducted [8].
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3.4. PSA and PSA Kinetics Threshold Levels
We assessed the performance of 68Ga-PSMA-11 PET/CT regarding pre-scan PSA levels by ROC
curve separating the two patient-groups RP and RT. Based on the results of previous studies [4,9],
which emphasized the importance of PSA kinetics for patient selection and detection, we also calculated
PSAvel and PSAdt (see introduction), as they are valuable parameters for the prediction of clinical
progression. However, it should also be borne in mind that there are non-PSA-producing tumor masses
in metastatic and fully treated PCs.
3.5. PSA and PSA Kinetics Threshold Levels (RP)
In our study, a PSA of 1.24 ng/mL was the optimal cutoff level for distinguishing between
positive and negative 68Ga-PSMA-11 PET/CT scans. 68Ga-PSMA-11 PET/CT showed the presence of
multimetastatic PC in 21% of the positive lesions in patients with PSA levels below the cutoff value
and in 79% in patients with PSA above the cutoff (Table 5A). Thus, we conclude that the cutoff by
hybrid imaging with 68Ga-PSMA-11 can be used for patient selection for restaging and also fits well
into clinical practice. If you convert 1.24 ng/mL to tumor mass, it might be a small LNM or tissue
volume of less than one cubic milliliter.
Significant differences between PET-positive and PET-negative patients were calculated with
corresponding optimal PSAvel threshold of 1.32 ng/mL/year (p < 0.001). Similarly to other studies,
our data show higher positivity rates corresponding to a higher PSAvel, which was also seen in
studies with 18F-choline. Like other authors, we propose that in addition to the PSA level, PSAvel
could be taken into account in patient selection [9,20,32,34]. On the other hand, a recent study, which
assessed a large cohort of patients, did not show significant correlation between 68Ga-PSMA-11 PET/CT
positivity and PSAvel [35].
In this study, PSAdt was not significantly associated with 68Ga-PSMA-11 PET/CT positivity.
For distinguishing between the positive and negative PSMA-PET findings, no optimal PSAdt cutoff
could be determined by ROC analysis (AUC = 0.450). The value of PSA in patient selection is
controversial [9]. Verburg et al. recommended combining serum PSA with PSAdt in order to achieve
the best PSMA-positive scan result or the detection of distant LNM; in which they emphasized the
importance of PSA over that of PSAdt [26]. Ceci et al. demonstrated PSAdt as a valuable predictor
of positive 68Ga-PSMA PET/CT scans and pointed out that patients with a short PSAdt and low PSA
values showed positive PSMA scans in 85% [36]. Corresponding to the EAU guidelines, these patients
were ideal candidates for salvage RT, as salvage RT has been described to be mostly efficient in patients
with short PSAdt [8,36]. In contrast, in the same study, 18.7% of patients had low PSA values, but long
PSAdt, and also showed positive PSMA-PET/CT findings [36].
3.6. PSA and PSA Kinetics Threshold Levels (RT)
In our study, we calculated an optimal PSA cutoff level from ROC curve of 5.75 ng/mL (Table 5B).
We were not able to determine an optimal PSAvel threshold for the irradiated patient-group based on
the available data. ROC analysis revealed a PSAdt cutoff of 10.6 months for the identification of RT
patients with positive and negative scans, which did not find significance (p = 0.353).
At the present time, our cutoff results cannot be compared with the results of other studies in
terms of thresholds, since they consider both (the prostatectomized and the irradiated patients) in
one common patient group. Otherwise, only the RP-group is analyzed. Radiation groups are rarely
examined alone for calculating cutoff levels.
3.7. Subpopulations
The performance of 68Ga-PSMA-11 PET/CT has to be appraised for a therapeutic approach.
In particular, the detection of local LNM should be considered, which could lead to a changed
therapeutic approach (salvage RP plus LNM dissection or salvage RT with extended radiation field).
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We took a closer look at PSA range between 0.2 ng/mL to < 1 ng/mL for post-prostatectomized patients
based on the EAU guidelines for performing PSMA PET/CT in different initial situations [8]. The
guidelines do not specify a threshold after primary radiation, so we have not formed a subgroup for
these patients [8]. In the RP-group, 29% of patients showed PSA values that were between 0.2 and < 1
ng/mL with a PSMA-positivity rate of 52%. There was a significant association between the pre-scan
PSA and an increased likelihood of a positive PSMA-scan was proven (p < 0.001). In comparison, Eiber
et al. demonstrated positive scans in 57.9% for PSA values of 0.2 to < 0.5 ng/mL and even 72.7% at
0.5 to < 1 ng/mL [20]. A published study by Graziani et al. showed that only about 45% of the scans
were positive while using hybrid imaging with 11C-choline PET/CT in patients, even with PSA levels
between 1 and 2 ng/mL. Multimetastatic disease was detected in 38% of all scans and distant lesions
in 19% of the patients with PSA levels between 1–2 ng/mL [37]. In the present study, 68Ga-PSMA-11
PET/CT revealed local metastases in 59%, multimetastatic disease in 44%, and distant lesions were
shown in 13% of the subpopulation patients. A clinically relevant number of patients can be selected
for salvage therapy due to the effectiveness of 68Ga-PSMA-11 PET/CT for the detection of metastases,
which is apparently higher than that of 11C-choline, possibly even for metastatic-directed treatment,
which might justify salvage LN dissection rather than systemic therapeutic path, thereby help to avoid
unnecessary procedures and complications and also improve the chance of a clinical recurrence-free
survival [38,39].
3.8. GS
Histopathological GS was significantly associated with positive 68Ga-PSMA-11 PET/CT results
(p < 0.001). Patients with GS of 7b (intermediate risk and grade group 3) and > 7 (high risk and grade
group 4 or 5) showed an increased incidence of positive 68Ga-PSMA-11 PET/CT scans (p < 0.001).
Between patients with PSMA-positive scans corresponding to GS 7a (intermediate risk and grade group
2) and PSMA-positive scans corresponding to GS 7b, there was a significant demarcation (p < 0.001).
Regarding the clinically important, highly significant differentiation between GS 7a (3 + 4) and 7b
(4 + 3), patients with GS 7b exhibited more frequent pathologic 68Ga-PSMA-11 PET/CT scans and
metastases [8,40]. Therefore, the findings of hybrid imaging with 68Ga-PSMA-11 agree in many cases
with higher risk relapses on the basis of histology (frequency and detection of metastases). Our results
are in line with other studies, which could possibly be due to the fact that the PSMA expression is
usually more intense in higher-grade GS lesions than in lesions with a lower-grade GS [8,12,23,41].
Our results correspond to the immunohistochemical results of PSMA expression in PC [20].
3.9. ADT
The positivity rate of 68Ga-PSMA-11 PET/CT was significantly correlated with accompanying
ADT in this study. This is in line with the results of a study, in which the ADT-treated patients revealed
positive PET/CT results more often and that was believed to be due to the frequent use of ADT in
patients with advanced disease [20]. The same phenomenon has also been described when using
11C-choline [37]. Furthermore, there have been reports of higher PSMA-expression of PC tumor cells
as part of ADT [42]. Overall, the scientific knowledge on this issue remains unclear and further studies
are needed [12,20].
3.10. AP
In our study, patients with PSMA-positive lesions showed higher AP levels than patients with
negative PSMA scans (p < 0.001). Additionally, the detection of bone metastases was significantly
associated with high AP. Our results corroborate the findings of other studies where serum AP was
found to be a predictor for bone involvement of PC and to be an efficient and reliable biomarker for the
prognosis of PC [43]. The AP levels were higher in patients with positive 68Ga-PSMA-11 PET/CT scan
results, with higher PSA levels, in patients receiving ADT and in patients exhibiting bone metastases
in our study. Li et al. suggest that high AP is significantly related to poor overall survival and poor
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progression-free survival in PC, but there is no apparent association to cancer specific survival [43].
Skeletal AP is prognostic for bone metastases for M-staging of PC, and it is a dependable marker of
osteoblastic activity. Another study demonstrated that AP levels were more closely associated with
pathological bone scans than with PSA values and that the amount of AP was positively related to
bone metastases [44]. From this, we conclude that the term “bone-specific AP” can reasonably be used.
4. Materials and Methods
4.1. Patient Characteristics
581 BC patients that had previously been treated with RP or RT, underwent 68Ga-PSMA-11
(Glu-urea-Lys(Ahx)-HBED-CC) PET/CT between 2015 and 2019 and were retrospectively evaluated.
The inclusion criteria for the performance of a 68Ga-PSMA-11 PET/CT scan were: (a) histopathologically
proven primary PC; (b) treatment with RP or RT (with or without ADT); and, (c) proven BC by definition
(BC is defined as an elevation of the PSA value after primary treatment to > 0.2 ng/mL after RP or
> 2 ng/mL above nadir following RT). The data on some of the patients included were already
considered in another study with different aim. The PSA levels were available at the time of surgery as
well as nadir, interim, and PET/CT scans (BC). Mean relapse PSA levels were 18.21 ng/mL ± 101.91
ng/mL (median 2.98, range 0.2–2000). 209 patients were treated with anti-androgens (Table 1). The
patient data were collected from four Nuclear Medicine Institutions (a–d) in Germany. We have
classified the patients into the following groups: (1) To obtain a clean statistic, we looked at the
patient-group after RP and the patient group after RT separately, as, by definition, they have a different
BC. (2) The subgroup of RP-patients was divided into five groups: 0.2 to < 0.5 ng/mL, 0.5 to < 1
ng/mL, 1 to < 2 ng/mL, 2 to < 5 ng/mL, and 5 ng/mL, and above. (3) The RT-patients were divided
into two groups: 2 to < 5 ng/mL and 5 ng/mL and above. Additionally, patients were assigned to
five-tiered GS groups: < 7, 7a and 7b, 8 and > 8, respectively. The following parameters were evaluated:
68Ga-PSMA PET/CT scan results, PSA values, PSA kinetics, SUVmax of the malignant lesions, GS, ADT,
AP and local/distant/single/multiple metastases, regional and/or distant LNM, bone metastases, and
visceral metastases (e.g., lung). The main limitation of this retrospective study as compared to many
other retrospective studies is that most of the patients did not have histopathological confirmation
of the lesions. As a result, we use the term positivity rate instead of detection rate in this study. In
addition to the histopathological findings (when available), we used a significant increase in PSA or
a decrease in PSA after subsequent therapy (e.g. salvage RT) or a confirmation of the pathological
focus in follow-up imaging or an increase and/or enlargement of the lesions in follow-up imaging,
as indicators. We evaluated the optimal cutoff level by calculating PSA and PSA kinetics thresholds
while using the ROC curve to determine the best time to perform 68Ga-PSMA-11 PET/CT scans in
patients with BC. The present study was in accordance with the Helsinki Declaration and the German
Medicinal Products Act, AMG §13.2b. The retrospective study was conducted in accordance with the
Declaration of Helsinki, and the Ethics Committee of Laek Rlp (2018-13390, approval date: 29 October
2018) and Aek No (41/2019, approval date: 22 February 2019) approved the protocol. All of the patients
gave their written informed consent for the examination and for inclusion in the study.
4.2. Radiopharmaceuticals
The 68Ga-labelled PSMA ligand, Glu-urea-Lys(Ahx)-HBED-CC (68Ga-PSMA-11), was synthesized
while using modification of a method described in 2012 [16]. In short, 68Ga was achieved from
a 68Ge/68Ga radionuclide generator (Garching, Germany) to be used to label the PSMA ligand.
The labelled tracer without carrier additive was cleaned using a reverse phase cartridge (Sep-Pak
C18 Plus Light cartridge, 130 mg Sorbent; Waters) and formulated in 10 mL phosphate-buffered
saline with 5% by volume ETOH. Confirmation by radio thin-layer chromatography (TLC) and
high-performance liquid chromatography (HPLC) was able to show a radiochemical purification yield
of over 98%. 68Ga-PSMA-11 was obtained from the Clinic of Nuclear Medicine of the Medical Center of
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the University Johannes Gutenberg (Mainz, Germany; b, c), from Advanced Accelerator Applications
(Bonn, Germany; b, c), from Eckert & Ziegler (Bonn, Germany; d) or was produced in house (Mainz,
Germany; a), depending on the availability.
4.3. Imaging Protocol
Each patient received an intravenous injection of 68Ga-PSMA-11 (mean and SD: 199 ± 61 MBq,
median activity: 200 MBq, range: 50–390 MBq). The PET data of tracer distribution were acquired
60 ± 10 min. (whole body) after injection of 68Ga-PSMA-11. The patients were imaged on a PET/CT
scanner named Gemini TF16 (Philips Medical Systems, Best, The Netherlands) (a, c) or a PET/CT
scanner, named Biograph 64/Z64, R4 (HD and time of flight)/Biograph 64 TruePoint (True V HD;
Siemens, Erlangen, Germany) (b, d). Either a mid-inspiratory low-dose CT scan (120 kV, 20–60 mAs,
CT transverse scan field 50 cm, 70 cm extended field of view, high contrast resolution 1.0 s, 0.6 mm)
without contrast enhancement or a maximum inspiratory venous-phase diagnostic contrast enhanced
(Ultravist 300; Bayer AG, Berlin, Germany) CT scan (140 kV, 100–400 mAs, dose modulation) from the
head to the upper-thigh was used for anatomical correlation and for attenuation corrections. PET was
performed while using a standard technique on a dedicated three-dimensional (3D) system (a, c: matrix
144 × 144; d: 400 × 400; b: 168 × 168), with an acquisition time of 3 min. per bed position (axial field of
view d: 13.3 cm; b: 21.8 cm; c: 19 cm; a: 18 cm). Random, scatter, and decay correction were applied to
the emission data. Ordered-subsets expectation maximization method (OSEM) (a: three iterations,
33 subsets, Gaussian filtering, 4.3 mm full-width at half-maximum; b, c: two iterations, 14 subsets,
Gaussian filtering, 5 mm (c) or 4.2 mm (b) transaxial resolution, full-width at half-maximum; d: three
iterations, 24 subsets, Gaussian filtering, 5 mm transaxial resolution, full-width at half-maximum) was
used for PET image reconstruction. The CT data were converted to attenuation coefficients at 511 keV
and applied for attenuation corrections of the PET images.
4.4. Imaging Analysis
The PET/CT images were first visually assessed by individual specialists (nuclear medicine
physician, radiologist) while applying coronal, transaxial, and sagittal layers. Subsequently, all of the
images were interpreted in consensus by at least one experienced nuclear medicine physician, and two
experienced radiologists, each of them board-certified and with PET/CT experience of more than five
years as well as rich experience in interpretation of hybrid imaging with 68Ga-PSMA-11. The final
diagnosis was reached by consensus. Any PSMA-avid lesion with a morphological substrate on CT and
an uptake above the background (but not correlated with physiological tracer uptake) was considered
as being suggestive of PC. The SUVmax was measured for all lesions, suspicious of malignancy.
PSMA-PET-avid lesions as described above were classified as suspected local recurrence in the prostate
or prostate bed, as local/regional LN in the pelvis (iliac and/or pararectal) or as distant/extrapelvic
LN (retroperitoneal and/or above the iliac bifurcation), as well as bone metastases and visceral
metastases (lung, liver, adrenals, soft tissue, spleen, thyroid). When conflicting interpretations were
identified, they were discussed and solved by the panel and consensus was passed between the
reviewing physicians.
4.5. Statistical Analysis
Statistical analyses were performed while using SPSS version 24.0 (IBM Corporation, Ehningen,
Germany). For continuous metric normally distributed variables, Students t-test was performed
to determine differences between two groups. Multivariate variance analysis was used for
comparison of more than two groups. We analyzed non-normally distributed continuous variables
by Mann-Whitney-U test. The Wilcoxon signed rank test was calculated for determining the changes
of PSA levels. For further analysis, we subdivided the metric values (e.g., PSAvel and PSAdt) into
categories. We analyzed these nominal and ordinal parameters with Chi-square test and Pearson
correlation. The performance of 68Ga-PSMA-11 PET/CT was assessed in relation to these parameters by
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ROC curves in order to determine the optimal cutoff of PSA levels and of PSA kinetics to differentiate
between positive and negative scan results. The data are presented as mean, SD, and/or median and
range. p < 0.05 was considered to be significant.
5. Conclusions
This study identifies the PSA and PSA kinetics thresholds for the presence of 68Ga-PSMA-11
PET/CT-detectable PC-lesions in patients with BC. Pre-scan PSA was the main predictor of a positive
scan with an optimal cutoff level of 1.24 ng/mL for patients that were primarily treated with RP. In this
subgroup, kinetics analysis of PSA calculated a threshold velocity of 1.32 ng/mL/year.
We conclude that the PSA levels and kinetics (PSAvel) are suitable risk markers for optimizing
the selection of patients who may benefit from 68Ga-PSMA-11 PET/CT, especially in the subgroup
of prostatectomized patients. 68Ga-PSMA-11 PET/CT has a great impact on selecting patients with
primary RP for salvage RT with curative intent.
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